Atrium Therapeutics, Inc.’s mission is to pioneer the delivery of ribonucleic acid (RNA) therapeutics to the heart to transform the standard of care for people living with cardiomyopathies. Our proprietary technology leverages the targeted RNA delivery platform initially developed at Avidity Biosciences, Inc., which combines the tissue selectivity of monoclonal antibodies (mAbs) and other targeted delivery ligands with the precision of oligonucleotides. Our precision cardiology pipeline currently consists of two primary, wholly owned precision cardiology development candidates for the treatment of PRKAG2 syndrome and PLN cardiomyopathy.

Atrium Therapeutics

Kathleen Gallagher

This department oversees the planning and execution of clinical trials and initiatives to ensure adherence to regulatory standards and project goals.

Clinical Operations

This department focuses on conducting experiments and research in various scientific disciplines.

Scientific Research

This department provides strategic direction and governance for the organization.

Executive Leadership

This department manages procurement processes and administrative support functions to facilitate operational efficiency.

Procurement and Administration

This department focuses on advancing scientific knowledge and developing innovative solutions through research and experimentation.

Research and Development

This department focuses on the discovery and development of biomarkers for various applications in healthcare and research.

Atrium Therapeutics

Org chart

Teams

Clinical Operations

Scientific Research

Executive Leadership

Procurement and Administration

Research and Development

Biomarker Research

Offices

Atrium Therapeutics

Org chart

Teams

Clinical Operations

Scientific Research

Executive Leadership

Procurement and Administration

Research and Development

Biomarker Research

Offices

Related companies